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AZD3409 is an orally active double prodrug that was developed as a novel dual prenyltransferase inhibitor. The formation of the
active metabolite AZD3409 acid is mediated by esterases in plasma and cells. The aim of this phase I study was to determine the
maximum tolerated dose, toxicities, pharmacokinetics and pharmacodynamics of AZD3409. AZD3409 was administered orally to
patients with advanced solid malignancies using an interpatient dose-escalation scheme starting at 500mg AZD3409 once daily.
Twenty-nine patients were treated at seven dose levels. The MTD of part A was defined as 750mg b.i.d. in the fasted state. Adverse
events were mainly gastrointestinal and the severity was on average mild to moderate and reversible. The dose-limiting toxicities
were vomiting, diarrhoea and uncontrolled nausea. Pharmacokinetic studies of the prodrug and the active metabolite indicated dose
proportionality. Pharmacodynamic studies showed that farnesyltransferase (FTase) was inhibited at all dose levels. In conclusion,
chronic oral dosing with AZD3409 is feasible and results in significant inhibition of FTase activity. Pharmacodynamic studies revealed
that the maximal FTase inhibition, estimated at 49±11%, appeared to be reached at AZD3409 acid plasma concentrations at which
the occurrence of drug-related toxicity was low. This study supports the rationale to implement biological effect studies in clinical
trials with biologically active anticancer drugs to define optimal dosing regimens.
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AZD3409 is a novel dual prenyl transferase inhibitor (DPTI)
developed for the treatment of cancer. Prenyl transferases
comprise a group of enzymes that are responsible for the
posttranslational addition of a farnesyl or geranylgeranyl moiety
to proteins that share a common C-terminal sequence, the
so-called CAAX-box (Casey and Seabra, 1996). One of these
proteins is the oncoprotein Ras. Ras exists in three isoforms:
H-Ras, N-Ras and K-Ras (with splice variants Ki4A and Ki4B). In
human cancer, the Ki4B-Ras protein is the most commonly
mutated Ras protein, and, therefore, it is an attractive target for
intervention in tumour development (Bos, 1989). In more recent
years, it has been shown that other farnesylated proteins such as
RhoB, Rheb and centromere proteins also play a role in tumour
development and are, therefore, interesting targets in cancer drug
development (Tamanoi et al, 2001; Delarue et al, 2007).
Initial drug development focused on the inhibition of farnesyla-
tion (Crul et al, 2001; Brunner et al, 2003). However, blockage of
farnesylation does not result in unprenylated Ki4B-Ras. Instead,
geranylgeranyl transferase (GGTase-1) takes over the posttransla-
tional modification of Ki4B-Ras, thereby preserving its function in
cell growth processes (Whyte et al, 1997). This could be a possible
underlying mechanism to the low-to-modest activity of farnesyl-
transferase (FTase) inhibitors in clinical phase II and III studies
(Sebti and Adjei, 2004). Clinical trials exploring FTase inhibitors in
combination with other anticancer drugs are still in progress
(Leary et al, 2007). Second-generation prenyl transferase inhibitors
have inhibitory properties on both FTase and GGTase-1 and are,
therefore, called DPTIs. It is expected that these drugs can
completely inhibit prenylation of Ki4B-Ras resulting in increased
clinical antitumour effects compared with FTase inhibitors.
AZD3409, developed by AstraZeneca, is an orally administered
DPTI that is administered as a double prodrug (Figure 1). In
plasma, it is rapidly converted to the circulating thiol-ester
prodrug. This is referred to as AZD3409 ester. The AZD3409 ester
can penetrate into the cell where a thiol-acid moiety is formed
under the action of esterases. This is the active drug and is referred
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sto as AZD3409 acid. It is a potent inhibitor of FTase (Kio1n M) and
a moderately potent inhibitor of GGTase-1 (Ki¼8n M) using Ki4B-
Ras as a substrate (Stephens et al, 2003).
In preclinical studies in mice bearing xenografts of H-Ras-
transformed mouse 3T3 fibroblasts (Hras5), and of 253J-BV or
RT-112 urothelial cells, significant reduction of tumour weight was
observed upon treatment with AZD3409 (Stephens et al, 2003;
Kelly et al, 2005). In mice bearing Hras5 tumours, growth
inhibition was correlated with inhibition of FTase activity. These
results provided a preclinical proof of the concept. Additionally,
biomarker assays were set up to determine the biological effect of
AZD3409 (unpublished data). The HDJ-2 and Rap1a prenylation
levels were chosen as suitable surrogate end points for farnesyla-
tion and geranylgeranylation, respectively. Preclinical proof of
concept and the availability of surrogate parameter assays were
considered to be a good starting point for a phase I clinical study.
The first trial with AZD3409 was performed in healthy male
volunteers. The main toxicities were diarrhoea (dose limiting at
2500mg once daily), nausea, dizziness, abdominal pain and
vomiting. The next lower dose of 1750mg was defined as the
maximum tolerated single dose in this group.
Here, we present our results of a phase I trial of AZD3409 in
patients with advanced cancer using a continuous daily dosing
scheme. The objectives of the study were (1) to investigate the
safety and tolerability of multiple oral doses of AZD3409 in
patients with advanced solid malignancies; (2) to investigate the
pharmacokinetic (PK) profile of AZD3409 ester and AZD3409 acid;
and (3) to investigate the degree of FTase inhibition after
administration of AZD3409 in surrogate and tumour tissue.
PATIENTS AND METHODS
Patient population
This phase I dose-escalating study of AZD3409 was a multicentre
study. Patients were eligible if they had histologically or
cytologically confirmed diagnosis of a solid malignant tumour.
Other eligibility criteria included a WHO performance status of
0–2 and age X18 years. Women with childbearing potential were
eligible when using contraceptive methods as defined by a method
of a failure rate less than 1% per year when used consistently and
correctly.
Previous chemotherapy and radiation therapy had to be
discontinued for at least 4 weeks before entry into the study. All
patients had to have acceptable bone marrow function, defined by
neutrophil counts X3.5 10
9/l, platelets X100 10
9/l and
HbX5.6mmol/l; and adequate hepatic and renal function defined
as creatinine clearance X50mlmin
 1, total bilirubin p1.5 times
the normal upper limit, and ASAT and ALAT p2.5 times the
normal upper limit (or p5 times the normal upper limit in case of
hepatic metastases). The Medical Ethics Committee of all hospitals
approved the study protocol and all patients had to give written
informed consent prior to start.
Treatment plan and study design
AZD3409 was supplied by AstraZeneca as 250mg capsules. It was
given once daily, after fasting from food and liquid for at least 1h.
During the study, the dosing regimen was switched from once
daily to twice daily (12h apart), because PK/pharmacodynamic
(PD) modelling based on data from a single ascending dose
volunteer study predicted that b.i.d. dosing would provide
prolonged FTase inhibition over a 24-h time period.
The study was divided into two parts. Part A was an open-label
dose-escalation study to define the maximum tolerated dose
(MTD). Part B was an enrichment phase in female patients having
advanced breast cancer for whom there was no standard therapy
available.
AZD3409 was administered continuously starting on day 1 of
each cycle of 21 days. A modified Fibonacci schedule was used for
dose escalation, starting from 500mg AZD3409. This dose was
predicted to achieve a steady-state exposure of approximately 25%
of the MTD observed in the healthy volunteer study. At least three
patients were treated at each dose level. The occurrence of a DLT
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Figure 1 Chemical structures of AZD3409. Reaction I: AZD3409 is
broken down by esterases in the plasma to from its major circulating
metabolite AZD3409 ester. Reaction II: After penetration into the cell,
AZD3409 ester is converted into the active drug AZD3409 acid under the
action of intracellular esterases.
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sin a patient during the first cycle led to enrolment of three
additional patients. Patients with progressive disease were
removed from the study and patients who were removed within
the first cycle of the study for reasons other than drug-related
toxicity were replaced.
Once the MTD was defined in part A an open-label safety run-in
phase commenced, with patients in part B being dosed in the fed
state, initially at 250mg b.i.d. At this point, a decision to stop the
clinical evaluation of AZD3409 was made and both the dose
escalation and the enrichment phase were not progressed.
Patient evaluation
Pretreatment evaluation included a complete medical history and
physical examination. Measurable and evaluable disease was
documented before the start of the study and during the study
as a basis for the assessment of clinical activity of the treatment.
Tumour response was recorded according to RECIST criteria
(Therasse et al, 2000). Toxicity was monitored at each visit. All
toxicities observed were graded according to the Common Toxicity
Criteria, version 2.0 (National Cancer Institute, 1998). DLT was
defined as any of the following events during the first treatment
cycle: grade 3 or 4 anaemia or thrombocytopaenia, febrile
neutropaenia grade 3, or grade 4 neutropaenia, grade 3 or 4
biochemical toxicity, grade 2 (or worse) nausea and vomiting
despite optimal antiemetic therapy, grade 3 or 4 diarrhoea despite
optimal loperamide support, failure to take study medication for 7
days or more within the first treatment cycle due to drug-related
toxicity or any CTC grade 3 or 4 nonhaematological toxicity
(excluding alopaecia). The MTD was defined as the dose below the
dose at which two or three of three, or two or more of six patients
experienced DLT during cycle 1.
Pharmacokinetics
Pharmacokinetic studies were performed in all patients. Ethylene-
diaminetetraacetic acid blood samples were collected during the
first cycle: on day 1 before the first drug intake and 0.5, 1, 2, 4, 6, 8,
12 and 24h after administration; on days 3, 8 and 15 before the
morning drug intake and 2h after administration; and on day 22
before the morning drug intake and 0.5, 1, 2, 4, 6, 8, 12 and 24h
after administration. Samples were immediately put on ice and
centrifuged at 41C for 10min at 1500g. The resulting plasma was
stored at  701C until analysis. Plasma samples of the last three
patients were not measured as the study was stopped before
analysis.
The total plasma concentrations of AZD3409 ester and AZD3409
acid were determined by LC–MS/MS. The plasma samples were
treated with dithiothreitol to reduce any disulphide bonds. The
sample pretreatment was based on protein precipitation with
acidic acetonitrile. Isotopically labelled analogues were used as
internal standards. The method has been validated regarding
selectivity, accuracy, precision and stability in human plasma. The
lower limit of quantification was 3ngml
 1 for both AZD3409 ester
and AZD3409 acid, with a 50 ml sample volume.
The following PK parameters were determined, either by direct
observation or by noncompartmental analysis (WinNonlin, ver-
sion 5.0.1; Pharsight, Mountain View, CA, USA): the minimal
plasma concentration (Cmin), the maximal plasma concentration
(Cmax), the area under the curve within one dosing interval
(AUC0 t) and total plasma clearance (Cl/F). Correlations between
dose and Cmax levels and between dose and AUC0 t were analysed
on day 1 using the nonparametric Spearman’s r (Rs) correlation
test. Accumulation was tested with an exact Wilcoxon’s rank
paired signed test. Linear measures mixed effects models were
constructed with SAS (SAS Institute Inc., Cary, NC, USA) to
determine the effect of the dose on the trough plasma concentra-
tions of both metabolites. The daily dose, time (days), gender and
age were considered to be a fixed effect, and the patient variable
was considered to be a random effect. Owing to the distribution of
the trough plasma concentration log transformation was applied.
Pharmacodynamics
Prior to and 2h after intake on days 1, 2 (only predose), 8 and 22,
whole-blood samples of 22.5ml were collected in heparinised tubes
for FTase activity determination in peripheral blood mononuclear
cells (PBMCs). Within 30min, the PBMC fraction was isolated
using Accuspin tubes (Sigma). The cell pellet was resuspended in
100ml lysis buffer (PBS containing 1% (v/v) Triton X-100, 0.5%
(w/v) sodium deoxycholate, 0.1% (w/v) sodium dodecylsulphate
and 1% (v/v) aprotinin) and stored at  701C.
FTase activity was measured by adding 5ml of PBMC lysate, 5ml
of lysis buffer and 10ml of water to each well. The lysates were
preincubated for 10min prior to the addition of 20ml of substrate
solution (either lamin B or K-Ras). The reaction was initiated by
the addition of 10ml of radiolabelled farnesylpyrophosphate (fpp).
The wells were incubated for 40min at 371C. The reaction was
stopped by the addition of 100ml of 1.5 M HCl in ethanol. The wells
were stored at 41C for 1h and then processed using the Tomtec
Harvester 96. The filter plates were dried at 371C for 15min, 0.35ml
MicroScint was added to each filter well and the radioactivity was
counted. Each lysate was analysed in triplicate. Blanks consisted of
the same reaction mixture without the substrate.
Linear mixed effects models were constructed to determine the
effect of time on the enzyme activity levels. In these models, the
daily dose, number of applications, time (days), measurement pre-
or postdrug intake, gender and age were considered to be a fixed
effect, and the patient variable was considered to be a random
effect. Owing to the distribution of the response variables, square
root variables were applied. Statistical analysis was performed with
SAS. To determine the correlation of the dose level and the enzyme
inhibition, a baseline was added to the described models.
Pharmacokinetic-pharmacodynamic correlations between the
active acid metabolite and decrease in FTase activity were fitted
with WinNonlin software. Only patients with a basal FTase activity
that was higher than 10pg fpp per mg protein per min were
included in the model. This cutoff value was arbitrary and was
chosen based on the available data (lamin B; mean: 28.0, SD: 14.2,
median: 27.8, 25% percentile: 19.1 and K-Ras; mean: 29.3, SD: 17.8,
median: 25.6, 25% percentile: 16.7). The decision to set a minimum
baseline FTase activity implicates that the model can only be used
for patients with a minimum FTase activity of 10pg fpp per mg
protein per min.
RESULTS
Patient characteristics
In total, 37 patients have been included in the trial, of whom 32
patients were entered in part A and 5 patients in part B. The
number of 37 patients included represents the number of patients
screened. Of these 37 patients, 29 patients were found eligible and
were dosed in this trial. Patients’ characteristics are presented in
Table 1. Median age of the patients was 59 years (range: 38–77
years) and most patients were in good general condition. Patients
had various tumour types; colorectal malignancies were most
frequent (31% of all dosed patients).
Treatment
In part A, a total of six dose levels of 500mg once daily, 1000mg
once daily, 750mg b.i.d., 1250mg b.i.d., 1750mg b.i.d. and 1500mg
b.i.d., respectively, was investigated. In part A, 26 patients fulfilled
the eligibility criteria and received medication. In part B, five
patients were screened to receive a dose of 250mg b.i.d. in the fed
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sstate. Two patients did not receive medication, because they did
not fulfil the eligibility criteria. The median duration of patients on
study was 6 weeks (range: 1–15 weeks). In total, 25 patients
discontinued study treatment early. The main reasons for
discontinuation of the treatment were worsening of the patients’
condition (12 patients) and occurrence of adverse events (10
patients). Two patients were unwilling to continue with the study
after 4 and 8 weeks, respectively, and one patient had to stop
medication after 3 weeks due to disease progression.
Toxicity
No significant haematological toxicity was observed during cycle 1
of the study with oral AZD3409. None of the 29 patients who were
evaluable experienced leucocytopaenia, thrombocytopaenia or
anaemia greater than CTC grade 2 or neutropaenia greater than
grade 1. However, in part B, one patient experienced CTC grade 3
thrombocytopaenia after stopping treatment with AZD3409. The
patient had advanced breast cancer with distant metastases in the
bone, liver and lung. The platelet counts decreased from 109 10
9/l
before start of treatment to 24 10
9/l on day 36, 2 weeks after end
of the medication.
The drug-related nonhaematological adverse events per patient
as a function of the dose are presented in Table 2. Nonhaemato-
logical toxicity was reported by many patients and consisted
mainly of vomiting (55%), nausea (55%) and diarrhoea (41%).
Adverse events were observed both in the once daily and the twice
daily regimens. The severity was on average mild to moderate and
reversible. However, at the dose level of 1750mg b.i.d., two
patients were unable to take the drug as a consequence of CTC
grade 2 vomiting in spite of antiemetics, and, therefore, this
toxicity was considered dose limiting. At the next lower dose level
of 1500mg b.i.d., two patients were also unable to continue
AZD3409 treatment due to grade 3 diarrhoea and uncontrolled
nausea (grade 2), respectively. Both toxicities were dose limiting,
and, therefore, the dose was further lowered to 1250mg b.i.d. In
total, three out of six patients at this dose level experienced grade 3
diarrhoea, grade 3 dehydration, grade 2/3 nausea and grade 2
vomiting. These gastrointestinal toxicities were also dose limiting.
The MTD of part A was defined as 750mg b.i.d. in the fasted state.
Tumour response
Eighteen patients were evaluable for tumour response after 4–14
weeks of treatment. No objective tumour response was observed.
Three patients (17%) had stable disease for 47, 48 and 76 days,
respectively.
Pharmacokinetics
Plasma concentrations of AZD3409 ester and AZD3409 acid were
measured in all 26 patients of part A and in none of the patients of
part B. The AZD3409 parent drug is rapidly metabolised in the gut
and plasma to the AZD3409 ester metabolite and therefore does
not appear in the blood. Complete plasma concentration–time
curves were obtained for both AZD3409 ester and AZD3409 acid
on days 1 and 22 (see Figure 2 for MTD level). The estimated PK
parameters for AZD3409 ester and AZD3409 acid at all dose levels
are presented in Table 3. Extrapolation of the AUC of AZD3409
ester and AZD3409 acid to infinity exceeded 20% in most cases and
therefore AUC values within one dosing interval (AUC0 t) were
reported. Also, terminal half-lives could not adequately be
estimated. Interpatient variability was high and the coefficient of
variation ranged between 45 and 103% for the AUC of AZD3409
ester and between 44 and 99% for the AUC of AZD3409 acid on
day 1.
A positive correlation between the dose and the AUC and Cmax
on day 1 was observed for both AZD3409 ester (Rs¼0.52 and 0.43)
and AZD3409 acid (Rs¼0.52 and 0.43). The plasma concentrations
Table 1 Patient characteristics
No. of patients
Total 29
Sex
Male 13
Female 16
Age (years)
Median 58
Range 38–77
Performance status
01 3
11 5
21
Unknown 0
Primary tumour location
Colorectal 9
Breast 6
Oesophagus 3
Skin/soft tissue 3
Pancreas 1
Kidney 1
Liver 1
Other 3
Unknown 2
Previous therapy
Chemotherapy 29
Radiotherapy 15
Other therapy 10
Table 2 Possibly or definitely drug-related nonhaematological toxicity in cycle 1 that was observed in more than 10% of all treated patients
Adverse event Grade Dose (mg)
Total
Number of patients 500 1000 750 b.i.d. 1250 b.i.d. 1500 b.i.d. 1750 b.i.d. 250 b.i.d. n (%)
3 3 8 624 3 2 9
Abdominal pain 1–2 1 2 3 (10)
Anorexia 1–2 1 2 1 2 6 (21)
Diarrhoea 1–2 3 3 2 4 12 (41)
3–4 1 1 2 (7)
Fatigue 1–2 1 2 1 1 5 (17)
Nausea 1–2 1 2 5 3 1 3 1 16 (55)
3–4 1 1 (3)
Vomiting 1–2 1 2 4 3 1 3 2 16 (55)
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sof AZD3409 ester were higher than those of AZD3409 acid.
Accumulation was shown for both metabolites, although only
significant for AZD3409 acid (P¼0.006). As a result of the slightly
higher acid accumulation, the AUCester/AUCacid ratio changed
from 2.5 on day 1 to 2.0 on day 22.
Statistical analysis of the mean predose concentration of
AZD3409 ester and AZD3409 acid on days 3, 8, 15 and 22 of the
first cycle demonstrated that the trough plasma concentrations
increased with the administered dose per day. However, after
performing a sensitivity analysis by including the number of
applications per day as a fixed effect, no correlation was found
between the Cmin and the daily dose. Gender and age did not affect
the trough concentrations. A slight increase of Cmin of the acid
metabolite over time was observed.
Pharmacodynamics
FTase activity was measured in 24 patients of part A and 3 patients
of part B using both lamin B (Figure 3) and K-Ras as substrates
(data not shown). Both patients at the dose level of 1500mg b.i.d.
were excluded for statistical analysis due to lack of data. For the
statistical analysis, no differentiation was made between parts A
and B. Enzyme inhibition was observed in all patients, although on
different days, except in patient 3 (dose level 500mgday
-1) and
patient 24 (dose level 750mg b.i.d.). Statistical analysis showed
that, as expected, on each day the degree of FTase inhibition after
intake was significantly higher than prior to intake of the drug
(Table 4). Over time, there was no significant drop of K-Ras values
for FTase activity, whereas the lamin B substrate values
significantly decreased (P¼0.02). In addition, it was investigated
whether an increase in daily dose affected the FTase inhibition. It
was shown that the FTase activity with the K-Ras substrate
significantly decreased (P¼0.03), but no effect was observed on
the FTase activity with the lamin B substrate. With regards to the
other variables, patient age, gender and number of doses per day
did not influence the outcome. When a correction for the baseline
values of FTase activity is included in the model, the K-Ras values
for FTase activity were not significantly decreased over time nor
with increasing daily dose. In contrast, the lamin B values for
FTase activity were decreased both over time (P¼0.04) and with
increasing daily dose (P¼0.02).
To reveal PK/PD relationships, the AZD3409 acid plasma
concentrations of 22 patients of part A were plotted against the
proportional decrease in FTase activity at equal sampling times.
Three and two patients for K-ras and lamin B, respectively, who
had an initial FTase activity lower than 10pg fpp per mg protein
per min were excluded. At first sight, there was no relationship.
However, when only the data of day 1 were used for this analysis,
we found that the lamin B data could be fitted to an Emax model
0
50
100
150
200
250
300
350
400
450
500
0 5 10 15 20 25
Time (h)
A
Z
D
3
4
0
9
 
c
o
n
c
e
n
t
r
a
t
i
o
n
 
(

g
 
m
l
–
1
)
0
50
100
150
200
250
300
350
400
450
500
0 5 10 15 20 25
Time (h)
A
Z
D
3
4
0
9
 
c
o
n
c
e
n
t
r
a
t
i
o
n
 
(

g
 
m
l
–
1
)
Day 1 
Day 22
Figure 2 Plasma concentration–time curve of AZD3409 ester
(diamond) and AZD3409 acid (square) during day 1 (upper) and day 22
(lower), respectively, in a patient receiving 750mg b.i.d.
Table 3 Pharmacokinetic parameters of AZD3409 ester and AZD3409 acid on days 1 and 22 after administration of AZD3409
Day 1 Day 22
Dose N
Cmax
(ngml
 1)
AUC0 s
(nghml
 1) N
Cmax
(ngml
 1) Cl/F (lh
 1)
AUC0 s
(nghml
 1)
Ratio AUC0 s
day 22/day 1
AZD3409 ester
500 3 82.1 (70.0) 395 (407) 2 [229–257] [263–308] [1230–1465] [1.42–8.31]
1000 3 318 (254) 1545 (788) 3 296 (96.9) 319 (172) 1934 (279) 1.54 (0.86)
750 b.i.d. 8 245 (152) 1066 (816) 3 298 (127) 309 (151) 1724 (656) 7.03 (8.46)
1250 b.i.d. 6 338 (190) 1777 (972) 4 366 (132) 474 (231) 2123 (788) 1.28 (0.70)
1500 b.i.d. 2 [227–315] [1456–1627] — — — — —
1750 b.i.d. 4 362 (154) 1693 (757) 1 445 1145 1098 0.97
AZD3409 acid
500 3 33.6 (25.4) 160 (159) 2 [95.9–111] [465–488] [712–775] [2.07–10.1]
1000 3 78.6 (24.6) 512 (229) 3 106 (15.5) 710 (148) 904 (113) 2.10 (1.19)
750 b.i.d. 8 93.8 (55.7) 468 (341) 3 138 (30.7) 473 (155) 934 (220) 9.29 (11.2)
1250 b.i.d. 6 119 (64.9) 677 (322) 4 168 (77.3) 785 (311) 1230 (704) 1.95 (1.05)
1500 b.i.d. 2 [83.5–148] [458–749] — — — — —
1750 b.i.d. 4 140 (62.6) 751 (260) 1 165 1706 466 1.23
—¼no data available; AUC0 s¼AUC within one dosing interval. Represented as mean and (standard deviation) or as [absolute values] when no3.
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s(Figure 4) using the following equation: E¼(Emax*C)/(CþEC50).
The maximal effect (Emax) was estimated at 49% (±11) and the
EC50 was 9.5 (±13.9) ngml
 1. The K-Ras data could not be fitted
due to high scatter.
Figure 5 presents the Emax model for lamin B as well as the Cmax
in cycle 1 vs the cumulative occurrence of grade 1–2 vomiting in
cycle 1 (n¼22). The time at which FTase activity was determined
was approximately 2h after administration, and the mean time
at which Cmax was reached was 2.7h. At approximately
100ngml
 1, 90% of the maximal biological effect is reached,
whereas the chance to suffer from vomiting due to the medication
is below 15% at maximal plasma concentrations up to
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Figure 3 FTase activity (pg fpp per min per mg protein) of each patient over time using lamin B as substrate, separated by pre- (upper) and post (lower)
treatment and by daily dose.
Table 4 Statistical significance of dosing variables on the inhibition of FTase activity in PBMCs of patients treated with different doses of AZD3409
Estimate P-value
Variable Baseline not included Baseline included Baseline not included Baseline included
Lamin B
Pre/post treatment 0.62 0.63 o0.001 o0.001
Time  0.025  0.023 0.02 0.04
Total dose  0.0002  0.0004 0.32 0.02
Doses per day 0.18 0.67 0.71 0.05
Age 0.00003  0.0053 1.0 0.67
Sex 0.61 0.17 0.09 0.49
Baseline NA 0.38 NA o0.001
K-Ras
Pre/post treatment 0.71 0.68 o0.001 o0.001
Time  0.016  0.013 0.10 0.18
Total dose  0.00073  0.00034 0.03 0.09
Doses per day  0.062 0.30 0.94 0.49
Age 0.035  0.0066 0.28 0.72
Sex 0.24  0.048 0.68 0.87
Baseline NA 0.56 NA o0.001
NA¼not applicable.
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 1. Similar results were obtained for nausea toxicity (data
not shown).
DISCUSSION
The presented phase I trial demonstrates that continuous oral
dosing of the novel DPTI AZD3409 is feasible. The maximum
administered dose was 1750mg b.i.d. The MTD was defined in part
A as 750mg b.i.d. in the fasted state.
AZD3409 is a double prodrug, which complicates its pharma-
cokinetic analysis. The drug is rapidly metabolised to AZD3409
ester when it enters the blood stream. Hydrolysis of the ester group
of AZD3409 ester to form AZD3409 acid is a major pathway in the
liver (unpublished data). As expected, both metabolites but not the
parent drug could be detected in plasma. The PK studies in our
trial showed a positive correlation between the AZD3409 dose and
the parameters AUC0 t and Cmax of both metabolites on day 1.
However, interpatient variability was considerable at all dose
levels. On day 22, no significant correlation could be established
between the dose of AZD3409 and the parameters AUC0 t and
Cmax of both metabolites. This could be due to the lower number of
patient data that were available on day 22 to estimate the PK
parameters. Otherwise, it is possible that a large interpatient
variability is observed as a result of the biological processes in the
blood stream and body. Differences in plasma levels may also be
caused by differences in plasma protein binding as described
below.
In this trial, mean trough ‘total’ AZD3409 concentrations in the
twice daily dosing levels ranged between 31.3 and 434ngml
 1
(assuming that AZD3409 ester and AZD3409 acid are the main
metabolites in plasma). In vitro, AZD3409 inhibits cell prolifera-
tion of tumour cells at IC50 values between 0.05 and 5mM, which
corresponds to 35–3500ngml
 1 (Kelly et al, 2005). Hence, the
achieved plasma concentrations are likely within the active range.
Nevertheless, a considerable fraction might be bound to plasma
proteins. Estimation of the plasma protein binding of AZD3409 is
very complex, because both AZD3409 ester and AZD3409 acid have
a free thiol group that can form covalent bonds with proteins as
disulphides. This is atypical of protein binding, which is normally
a physical, rather than chemical association. It has been suggested
that glutathione reduces the measured protein binding, possibly
acting as an alternative partner in the formation of a disulphide. In
addition to forming disulphides with endogenous thiol-containing
compounds, such as proteins and glutathione, the free thiol-
containing metabolites may form disulphides with each other.
Extraction of AZD3409 ester and AZD3409 acid from plasma is
performed after reduction with dithiothreitol, which means that
the concentrations determined may have existed in plasma as a
complex mixture of disulphides. Therefore, at this stage, it has not
been established which fraction of analytes present in plasma
represents active drug (unpublished data).
Estimated clearance/F of both metabolites was very high, which
could be explained by low absorption of the parent drug from the
gastrointestinal tract. In a pilot mass balance study in rats, only 1%
of the given radioactivity was excreted in the urine supporting low
absorption of orally dosed AZD3409 from the gut (Kelly et al,
2005).
The AUCester/AUCacid ratio was slightly decreased on day 22.
This is probably due to the higher accumulation of AZD3409 acid.
Another explanation might be induction of esterases that convert
AZD3409 ester into the acid form. However, in vivo,n o
biologically significant changes were observed in cytochrome
P450 content or enzyme activity after once daily, oral dosing to
rats for 28 days (unpublished data).
In vitro, AZD3409 is a potent inhibitor of FTase. In this trial, PD
analysis showed that FTase activity in PBMCs could significantly
be inhibited by AZD3409 during 21 days of oral administration. At
predose time points after repeated dosing, the AZD3409 acid
concentrations were near the limit of quantitation, while the FTase
inhibition in PBMCs persisted. This indicates that continuous
inhibition of FTase can be accomplished by daily dosing of
AZD3409. Furthermore, the plasma concentrations of AZD3409
acid on day 1 could be adequately correlated to the relative
decrease of FTase activity by an Emax model. Two patients were
excluded from this model, because they had a low FTase activity at
the start of the study (o10pg fpp per mg protein per min)
compared with all other patients (mean¼31pg fpp per mg protein
per min). A very low basal activity implies that inhibition cannot
be measured. The maximal decrease in activity was estimated at
49%, indicating that FTase could not completely be inhibited.
Similar inhibition values were found in studies with single FTase
inhibitors (Cohen et al, 2003; Alsina et al, 2004; Cortes et al, 2005;
Tabernero et al, 2005). In the Calu-6 xenograft model, inhibition of
FTase by 66% was associated with a reduction of the tumour
volume of 15% (unpublished data). It has to be established
whether the level of inhibition of FTase that was seen in PBMCs in
this trial will translate into meaningful antitumour activity. Only 3
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Figure 4 Emax model of the AZD3409 acid plasma concentrations and
the matching relative decrease in lamin B FTase activity in PBMC lysate on day
1. Blood samples were taken 2h after intake of AZD3409. The maximal level
of FTase inhibition was estimated at 49%. The concentration, at which 50% of
the maximal effect is reached, was estimated at 9.5ngml
 1.C o r r e l a t i o nEmax/
EC50¼0.85, bias¼ 0.18% and precision¼21.1%.
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Figure 5 The cumulative occurrence of CTC grade 1–2 vomiting vs the
maximal AZD3409 acid plasma concentration during days 1–22. The Emax
curve from Figure 4 is also shown. The maximal biological effect is reached
at lower plasma concentrations than the toxicity of vomiting.
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The EC50 value in the Emax model of the lamin B substrate
was estimated at 15.2ngml
 1 AZD3409 acid in plasma.
This suggests that the mean trough total AZD3409 acid
concentrations in the twice daily dosing levels (36.3–81.9ngml
 1,
see also Figure 2) were high enough to cause at least 75% of the
maximally achievable FTase inhibition. It is unknown whether
there is a relationship between the observed inhibition of FTase
activity as documented in PBMCs and FTase activity in tumour
cells.
The occurrence of grade 1–2 vomiting was plotted against the
Cmax, because it was assumed that this drug-related toxicity is
mainly determined by the maximal plasma concentration. The
results indicate that maximal FTase inhibition is reached at
exposure levels that are lower than levels associated with induction
of significant vomiting.
Although the PK/PD analysis of AZD3409 acid is preliminary,
the approach may be meaningful for selecting the optimal dose of
the drug. Currently, it is unclear whether compounds that are not
directly cytotoxic, but target a biological pathway should be dosed
based on their maximal toxicity or on their maximal biological
effect (Workman, 2002; Garrett et al, 2003; Appels et al, 2005). We
showed that 90% of the maximal biological effect was reached at
AZD3409 acid plasma concentrations that were not toxic.
In conclusion, we have demonstrated that chronic oral
dosing with AZD3409 is feasible. We proved the concept that
AZD3409 can inhibit FTase activity in surrogate cells,
that is, PBMCs. It is, however, unclear to what level FTase
activity is inhibited in tumour tissue and whether the observed
inhibition of FTase in PBMCs will be sufficient for antitumour
activity. In addition, PD studies revealed that the maximal FTase
inhibition is reached at AZD3409 acid plasma concentrations at
which the occurrence of drug-related toxicity is low. The estimated
maximal FTase activity is approximately 50% and future
studies are warranted to determine the antitumour activity of
AZD3409 when dosed twice daily. This study supports the
rationale to implement biological effect studies in clinical trials
with biologically active anticancer drugs to define the optimal
dosing regimen.
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